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Abstract
Background: CDKN2A/p16INK4a is frequently altered in human cancers and it is the most important
melanoma susceptibility gene identified to date. p16INK4a inhibits pRb phosphorylation and induces
cell cycle arrest, which is considered its main tumour suppressor function. Nevertheless, additional
activities may contribute to the tumour suppressor role of p16INK4a and could help explain its
specific association with melanoma predisposition. To identify such functions we conducted a
yeast-two-hybrid screen for novel p16INK4a binding partners.
Results: We now report that p16INK4a interacts with the chromatin remodelling factor BRG1. We
investigated the cooperative roles of p16INK4a and BRG1 using a panel of cell lines and a melanoma
cell model with inducible p16INK4a expression and BRG1 silencing. We found evidence that BRG1
is not required for p16INK4a-induced cell cycle inhibition and propose that the p16INK4a-BRG1
complex regulates BRG1 chromatin remodelling activity. Importantly, we found frequent loss of
BRG1 expression in primary and metastatic melanomas, implicating this novel p16INK4a binding
partner as an important tumour suppressor in melanoma.
Conclusion:  This data adds to the increasing evidence implicating the SWI/SNF chromatin
remodelling complex in tumour development and the association of p16INK4a with chromatin
remodelling highlights potentially new functions that may be important in melanoma predisposition
and chemoresistance.
Background
The cyclin dependent kinase inhibitor p16INK4a is fre-
quently inactivated in human cancers and is a highly pen-
etrant melanoma susceptibility gene; more than 50
germline mutations have been identified in high-risk
melanoma-prone families [1]. The principal function of
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p16INK4a is to inhibit cell cycle progression by preventing
the cyclin dependent kinases CDK4 and CDK6 from phos-
phorylating the retinoblastoma protein, pRb. In the pres-
ence of p16INK4a, pRb remains hypophosphorylated and
forms active pRb-E2F transcriptional repressor complexes
that silence genes required for S-phase entry. Conse-
quently, ectopic expression of p16INK4a promotes pRb-
dependent G1 cell cycle arrest and senescence. Moreover,
functional p16INK4a is commonly maintained in pRb-defi-
cient tumors (reviewed by Sherr & Roberts [2]), and this
underscores the dependency of p16INK4a on the pRb path-
way.
Hypophosphorylated pRb can repress gene transcription
at least partly by remodelling chromatin structure through
its interactions with proteins such as HDAC1, BRM and
BRG1 [3-5]. As the catalytic core of the SWI/SNF chroma-
tin remodelling complex, the interaction between BRG1
and pRb was proposed to recruit the complex to E2F
responsive promoters and enhance pRb transcriptional
repressor activity. [5] There is also evidence that BRG1 acts
upstream of pRb by repressing cyclin D1 expression [6]
and upregulating the expression of the CDK inhibitors
p21Waf1, p15INK4b and p16INK4a [7-9] to maintain pRb in
an active, hypophosphorylated state. Not surprisingly,
BRG1 may function as a tumor suppressor; BRG1
hemizygous mice are susceptible to tumors [10], while
complete loss of BRG1 potentiates lung cancer develop-
ment [11] and BRG1 is silenced or mutated in human
tumor cell lines derived from breast, ovarian, lung, brain
and colon cancers [4,12]. BRG1 is also lost in established
neuroendocrine carcinomas and adenocarcinomas of the
cervix [13], and the loss of BRG1 expression in lung cancer
is associated with a poor prognosis [14,15].
In this study, it is identified for the first time that BRG1
specifically associates with p16INK4a in vivo, and that both
proteins are frequently lost in human melanomas.
Although both BRG1 and p16INK4a regulate pRb activity
we found no evidence that p16INK4a and BRG1 co-operate
in cell cycle regulation. Targeted silencing of BRG1 did not
diminish pRb-dependent p16INK4a  activities; p16INK4a
retained potent cell cycle inhibitory activity and induced
senescence in the presence and absence of BRG1. Contrary
to previous reports, that BRG1-deficient cells are relatively
resistant to p16INK4a-induced cell cycle arrest [16], we
show that pRb activity is BRG1-independent and thus,
BRG1 does not influence p16INK4a-mediated cell cycle
inhibition. Together with the frequent loss in primary
melanomas the novel BRG1 interaction with the
melanoma associated tumor suppressor p16INK4a implies
an important role for BRG1 in melanoma.
Results
BRG1 binds p16INK4a
From a yeast two-hybrid screen using full-length human
p16INK4a as bait, we isolated the C-terminal 530 amino
acids of the chromatin remodelling factor BRG1 as a
potential binding partner (Figure 1A). This segment of
BRG1 incorporates the ATPase domain, which facilitates
ATP hydrolysis, and the bromodomain, which enables
binding to acetylated histones [17]. To confirm that full-
length BRG1 also binds p16INK4a in human cells, both pro-
Identification of BRG1 as p16INK4a binding partner Figure 1
Identification of BRG1 as p16INK4a binding partner. A 
Schematic illustration of BRG1 highlighting the domains iso-
lated in the yeast 2-hybrid screen (Y2H clone) B U2OS cells 
were transfected with MYC-p16INK4a and FLAG-BRG1 or 
control vector and immunoprecipitations were performed 
with a mouse-anti-FLAG antibody or a matched mouse IgG 
as indicated. BRG1 and p16INK4a were detected on immunob-
lots with anti-FLAG and anti-MYC antibodies. C Fluorescent 
microscopy images (FM) and confocal microscopy images 
(CF) of SW-13 cells grown on cover slips and transfected 
with MYC-p16INK4a and FLAG-BRG1 and probed with anti-
FLAG and anti-MYC antibodies.Molecular Cancer 2009, 8:4 http://www.molecular-cancer.com/content/8/1/4
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teins were co-expressed transiently in U2OS osteosarcoma
cells and MYC-tagged p16INK4a was specifically co-purified
with FLAG-tagged BRG1 in immunoprecipitation assays
using a FLAG-specific antibody (Figure 1B). Further, when
both proteins were co-expressed in the SW-13 adrenocor-
tical carcinoma cell line, they co-localized in the nucleus
in distinct nuclear speckles (Figure 1C).
To verify that endogenous BRG1 also interacts with
p16INK4a, we initially utilized the WMM1175_p16INK4a
inducible melanoma cell model, which we have previ-
ously described [18]. p16INK4a expression was induced
with IPTG to reach physiologically relevant levels compa-
rable to those seen in the WS-1 normal human dermal
fibroblasts at passage 20 (Figure 2A). Using a p16INK4a-
specific antibody we isolated BRG1 from nuclear
WMM1175_p16INK4a lysates (Figure 2B). Importantly, the
interaction between BRG1 and p16INK4a was also con-
firmed in WS-1 normal human dermal fibroblasts at pas-
sage 20, using a p16INK4a-specific antibody (Figure 2C).
pRb pathway in human cell lines
To establish the role of BRG1 on p16INK4a function we
selected six cancer cell lines, varying in their p16INK4a, pRb
and BRG1 status [12,16]. As shown in Figure 3 and Table
1, p16INK4a expression was inversely related to pRb expres-
sion and only detected in the pRb-negative SAOS-2 oste-
osarcoma and C33A cervical cancer cells. All other cell
lines had detectable pRb and no p16INK4a. (Note, there is
a slight leakage of the ectopically introduced p16INK4a in
the p16-inducible WMM1175_p16INK4a  cells without
IPTG upon long exposure.) The BRG1 homologue, BRM
was expressed in all but the C33A cells and SW-13 adren-
ocortical carcinoma cells. Importantly, SW-13 and C33A
cells were also negative or extremely low for BRG1 expres-
sion levels. The H1299 lung cancer cells were deficient for
BRG1 expression, and all remaining cell lines had detect-
able levels of BRG1. It is also worth noting that the
HCT116 cells carry only a mutated, functionally impaired
BRG1 allele (BRG1Leu1163Pro) [12]. CDK4 was expressed
strongly in all cell lines, while its homologue, CDK6 was
either absent or poorly expressed in the pRb negative
SAOS-2 and C33A cells and present in the remaining cells.
p16INK4a requires pRB to induce cell cycle arrest
To define the impact of BRG1 on p16INK4a function we
transiently expressed either BRG1, p16INK4a or both pro-
teins in this panel of six cell lines. The short-term expres-
sion of BRG1 alone had no effect on the cell cycle
distribution of the cell lines tested. As expected, neither
p16INK4a alone nor p16INK4a in combination with BRG1
promoted cell cycle arrest in cells deficient for pRb (SAOS-
2 and C33A). In contrast, introduction of p16INK4a
induced potent cell cycle arrest in all cell lines expressing
pRb (U2OS, H1299, HCT116, SW-13) even when the cells
lacked BRG1 (H1299) or carried a reported mutant form
of BRG1 (HCT116) [12]. Further, co-expression of BRG1
did not significantly enhance the p16INK4a induced cell
cycle arrest in the U20S, H1299 or HCT116 cells. Impor-
tantly even in SW13 cells, which lack both BRG1 and its
homologue BRM, p16INK4a expression alone induced a sig-
nificant cell cycle arrest and this was enhanced to some
extent by over-expressing BRG1 (Figure 4). These data
BRG1 binds p16INK4a in melanoma cells and normal fibrob- lasts Figure 2
BRG1 binds p16INK4a in melanoma cells and normal 
fibroblasts. A 50 μg of total cell lysates derived from unin-
duced (-) and induced (+) WMM1175_p16INK4a cells and WS-
1 fibroblasts (passage 20) were separated using a 15% SDS-
PAGE gel. Immunoblots were probed for p16INK4a and β-
actin as indicated. B WMM1175_p16INK4a cells were induced 
to express p16INK4a with 4 mM IPTG or mock treated for 72 
hours. Immunoprecipitations were performed using a mouse 
anti-p16INK4a antibody or a matched mouse IgG from nuclear 
cell lysate, as indicated. Immunoblots were probed for 
endogenous BRG1 and induced p16INK4a using a mouse anti-
BRG1 and rabbit anti-p16INK4a, respectively. C Endogenous 
BRG1 was co-immunoprecipitated with p16INK4a from WS-1 
normal dermal human fibroblasts grown to passage 20 as 
detailed above.Molecular Cancer 2009, 8:4 http://www.molecular-cancer.com/content/8/1/4
Page 4 of 12
(page number not for citation purposes)
confirm that p16INK4a-induced cell cycle arrest requires
intact pRb, but not BRG1.
p16INK4a does not require BRG1 to promote cell cycle 
arrest or induce cell senescence
To thoroughly evaluate any functional interaction
between p16INK4a and BRG1, we stably silenced BRG1 in
the inducible WMM1175_p16INK4a cell model. These cells
were transfected with a silencing molecule specifically tar-
geting BRG1 or a non-specific (NS) silencing molecule
directed to the luciferase transcript. Two BRG1-silenced
clones, WMM1175_p16INK4a_siBRG1 W9 and X1, with >
95% reduction in BRG1 accumulation and two control
clones WMM1175_p16INK4a_sicontrol E1 and X2, with
unaltered BRG1 expression, were selected for analysis. All
clones remained inducible for p16INK4a expression (Figure
5A, B).
Silencing of BRG1 had no significant impact on the prolif-
eration rate or cell cycle distribution of the
WMM1175_p16INK4a cell line. In the absence of BRG1,
p16INK4a retained the ability to inhibit the proliferation of
the WMM1175 cells (Figure 5C), and this was associated
with arrest in the G1-phase of the cell cycle with a con-
comitant S-phase inhibition (Figure 5D) that was main-
tained over the five-day induction period (data not
shown). Moreover, the silencing of BRG1 had no impact
on the ability of p16INK4a to totally prevent outgrowth of
colonies upon low seeding density (Figure 5E).
BRG1 has been reported to induce senescence in SW-13
cells and in mesenchymal stem cells [7,19] and the role of
p16INK4a  in initiating and maintaining senescence is
widely acknowledged (reviewed by Huschtscha & Reddel
[20]). We investigated the role of BRG1 in p16INK4a-
induced senescence. The long term induction of p16INK4a
in WMM1175_p16INK4a cells was not influenced by the
BRG1 status, caused pRb hypophosphorylation (Figure
6A) and induced senescence-like features in the
pRb pathway proteins in cell lines Figure 3
pRb pathway proteins in cell lines. Expression of BRG1 
and BRM was analyzed using 50 μg of nuclear cell lysates. All 
other proteins were analyzed from 50 μg of total cell lysates.
Table 1: pRb pathway proteins in cell lines
WMM1175-wtp16 U20S Saos-2 HCT116 H1299 C33A SW13
BRG1 + + + mutant - low -
BRM + + +++ - -
pRb ++ - + + - +
CDK6 low + low low + - +
CDK4 + + +++ + +
p16 (-) -+ - -+-
Expression of the indicated proteins is summarized with + or -. Mutant status of BRG1 in HCT-116 cells has been reported [12].Molecular Cancer 2009, 8:4 http://www.molecular-cancer.com/content/8/1/4
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WMM1175 cells as reported previously [18,21], (Figure
6B). These features included increased cell size and gran-
ularity, positive senescence-associated β-galactosidase
activity and the appearance of senescence-associated hete-
rochromatin foci. Formation of foci coincides with the
recruitment of pRb to E2F-responsive promoters and is
associated with the stable repression of E2F-target genes
[22]. This important marker of pRb activity was not
affected by BRG1 silencing. Similarly, BRG1 silencing did
not alter the build up of SA-β-galactosidase induced by
p16INK4a (Figure 6B) or p16INK4a induced changes in cell
size and granularity in the WMM1175 cells (Figure 6C),
the latter corresponds to senescence associated vacuolisa-
tion. This data confirms that cell cycle regulation and
induction of cell senescence by p16INK4a does not require
BRG1.
BRG1 is lost in melanoma
To evaluate the role of BRG1 in melanomas, we examined
immunohistochemically stained paraffin sections from
archival paraffin-embedded tissue blocks of a series of pri-
mary and metastatic melanomas for expression of the
chromatin remodelling factor BRG1 and p16INK4a (Figure
7). As presented in Table 2, BRG1 expression was undetec-
table in 26/38 of melanomas (68%), whereas its homo-
logue, BRM, was detected in 40/50 (80%) of melanoma
specimens. As expected, p16INK4a was only detected in a
small proportion 20% (9/45) of these primary and meta-
static melanomas. Of 21 tumor samples with expression
data for p16IN4a and BRG1 18 (86%) had lost at least one
of these proteins, predominantly p16INK4a, and among
these were 10 tumors (48%) negative for both, while 3
samples 14% had retained expression of both p16INK4a
and BRG1. BRM and BRG1 showed consistent nuclear
localisation in all samples, while p16INK4a was found to
localise to the nucleus and cytoplasm. The proportion of
BRG1 expression was slightly higher in the metastatic
melanomas than in the primary melanomas, but, this did
not reach significance using a Mann-Whitney Wilcoxon
test. BRG1 and p16INK4a were readily detectable in cul-
tured, normal, primary human melanocytes (data not
shown) and therefore our data imply that BRG1-loss has
an important role in melanoma development.
Discussion
The p16INK4a tumor suppressor has a critical influence on
melanoma tumorigenesis. We have now shown that the
chromatin remodelling factor BRG1 is a novel binding
partner of p16INK4aand confirm this interaction in vivo.
More importantly, we show that loss of BRG1 occurs fre-
quently in primary and metastatic melanomas and pro-
pose that BRG1 may play an important role as a tumor
suppressor in this cancer.
We have also shown that p16INK4a requires pRb, but not
BRG1 to promote cell cycle arrest. This differs from several
previous findings in the literature but agrees with others:
It has been suggested that the pRb-BRG1 interaction is
required for the pRb repression of E2F-target genes such as
cyclin E and cyclin A, and thereby cell cycle arrest. Accord-
ing to this hypothesis, cells lacking BRG1 would harbor
only inactive pRb, thus conferring resistance to p16INK4a
induced growth arrest [5,16]. These findings differ from
those of Bultman et al. [23] who did not observe a func-
tional interaction between pRB and BRG1 in their murine
models and Kang et al. [7], who showed that the BRG1-
pRB interaction was not required for BRG1 induced cell
cycle arrest in SW-13 cells. In contrast to our work, Kang
et al. [7] used long-term BRG1 expression, which caused
growth arrest in SW-13 cells, and showed that BRG1
bound the p21Waf1 promoter and upregulated its expres-
sion 3–7 days after BRG1 expression. This was sufficient to
induce cell cycle arrest and senescence independent of the
BRG1 ability to complex with pRb. In this study we have
clearly demonstrated that p16INK4a requires pRb, but not
BRG1, to promote cell cycle arrest. Our data is mainly
based on the thorough analysis of a well-defined
melanoma cell model, with inducible physiological rele-
vant expression levels of p16INK4a and the use of highly
specific BRG1-silencing molecules. In this model,
p16INK4a induction promotes rapid G1-cell cycle arrest fol-
lowed by cellular senescence, and these functions were
not affected by silencing of BRG1.
BRG1 and p16INK4a in cell cycle regulation Figure 4
BRG1 and p16INK4a in cell cycle regulation. Indicated 
cell lines were transfected with MYC-p16INK4a, FLAG-BRG1 
and/or a control vector plus GFP-spectrin. Cells were fixed 
with 70% ethanol 48 hours post transfection and cellular 
DNA was stained with propidium iodide. Percent S-phase 
change of GFP-spectrin positive cells was calculated (percent 
S-phase vector control - percent S-phase sample) × 100/per-
cent S-phase vector control.Molecular Cancer 2009, 8:4 http://www.molecular-cancer.com/content/8/1/4
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BRG1 does not alter p16INK4a cell cycle regulation Figure 5
BRG1 does not alter p16INK4a cell cycle regulation. A 50 μg of nuclear lysates from WMM1175_p16INK4a clones with sta-
bly integrated siRNA targeting BRG1 or a non-specific (NS) control siRNA were probed for BRG1 and topoisomerase II (Topo 
II) as a loading control. B 50 μg of total cell lysates extracted from WMM1175_p16INK4a cells stably expressing either a BRG1-
specific siRNA or a non-specific (NS) siRNA molecule, as indicated, were treated with PBS (-) or IPTG (+) for 24 h and probed 
for p16INK4a and β-actin. C Cell proliferation was determined by MTS assay. D A proportion of the IPTG/mock treated cells 
were analyzed for changes in cell cycle distribution. Percent S-phase change was calculated (percent S-phase mock treated cells 
– percent S-phase IPTG treated cells) × 100/percent S-phase mock treated cells. E The same clones were seeded at low den-
sity (103 cells/7.5 cm plate) and p16INK4a expression was induced with 4 mM IPTG or cells mock treated and colony forming 
ability was assayed after 14 days.Molecular Cancer 2009, 8:4 http://www.molecular-cancer.com/content/8/1/4
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BRG1 does not alter p16INK4a driven senescence Figure 6
BRG1 does not alter p16INK4a driven senescence. WMM1175_p16INK4a cells, BRG1 silenced (clone X1, left panel) or NS 
(clone E1, right panel), were exposed to 4 mM IPTG over a five-day period and analyzed by FACS analysis, Western blot and 
imunocytostaining: A 50 μg of total cell lysate were immunoblotted and probed for p16INK4a, phospho-pRb (pRbSer807/811) and 
as a loading control β-actin. B The accumulation of p16INK4a, the cell proliferation marker Ki67, chromatin condensation 
(DAPI) and the appearance of SA-β-gal was analyzed by immunocytostaining in WMM1175_p16INK4a. Enlarged images of cells 
(indicated with arrows) show DAPI-stained chromatin foci. Histograms correspond to the average ± s.d of at least two inde-
pendent induction experiments from a total of at least 500 cells. LM, light microscopy. C FACS analysis by Forward Scatter 
(FSC) and Side Scatter (SSC) of clones demonstrate the senescence associated increase of cell size (FSC) and granularity (SSC) 
upon p16INK4a induction.Molecular Cancer 2009, 8:4 http://www.molecular-cancer.com/content/8/1/4
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Chromatin changes, which involve chromatin remodel-
ling, are an important step in p16INK4/pRb dependent
senescence [24]. It was recently shown that the BRG1
homologue, BRM, forms an initiating component of het-
erochromatin complexes during the senescence of
melanocytes [25]. BRG1 has also been implicated in
senescence of melanocytes, as it has been identified in the
SWI/SNF complex facilitating transcription in response to
IGFBP7, the latter itself being an important player in
oncogenic BRAF-induced senescence [26]. However, our
data show that p16INK4a is able to promote senescence in
WMM1175 melanoma cells in the absence of BRG1 indi-
cating that the p16INK4a/pRb senescence pathway does not
require BRG1.
As the catalytic component of the SWI/SNF chromatin
remodelling complex, BRG1 facilitates unwinding of
DNA helices bound to and wrapped around histone struc-
tures. The SWI/SNF chromatin remodelling complex can
be recruited by specific DNA binding molecules such as
transcriptional activators or repressors and directed to
specific DNA targets. For instance, BRG1 promotes p53
dependent transcription by interacting with this tumor
suppressor [27,28], while it functions as a co-repressor of
E2F dependent transcription by associating with the E2F
transcriptional repressor pRb [5]. Furthermore, BRG1 has
recently been reported to promote transcriptional activity
of the melanocyte specific transcription factor MITF-M
[29]. MITF-M plays an important role in melanocyte pro-
liferation and survival (reviewed by Goding) [30] and
activates the expression of p16INK4a [31]. It is possible that
the p16INK4a interaction with BRG1 modulates any one or
more of these functions. For example it is tempting to
speculate that p16INK4a influences MITF-M transcriptional
activity via its association with BRG1. This would create
an important feedback loop between MITF-M and
p16INK4a. We are currently investigating the impact of
p16INK4a on these BRG1 specific chromatin remodelling
functions.
Regardless of the function of the BRG1-p16INK4a complex,
it is evident that BRG1 expression can be lost relatively
early in melanoma development, with a significant pro-
portion (> 70%) of primary melanomas showing no
detectable BRG1 expression, while BRM expression was
usually maintained in these tumors (< 20% loss). Overall,
the rate of BRG1 loss was high in melanomas and compa-
rable to that of p16INK4a [32], which suggests that selection
against BRG1 expression arises relatively early in
melanoma genesis. The fact that, additionally to the fre-
quent loss of either tumor suppressor, a high proportion
of melanomas show loss of both proteins correlates with
our data showing BRG1-independence of the p16INK4a cell
cycle regulatory functions and this suggests BRG1 inde-
pendent and dependent functions of p16INK4a. BRG1 is
proposed to be an important modulator of chromatin in
melanocytic cells. In particular, BRG1 promotes transcrip-
tional activity of the melanocyte specific transcription fac-
tor MITF-M [29], reduction of BRG1 expression in
zebrafish embryos leads to a reduction in neural crest
derived cells including melanocytes [33] and thirdly we
found BRG1 expression in normal, primary human
melanocytes. Therefore we propose that BRG1 is a vital
melanoma associated tumour suppressor, which is fre-
quently lost in the initial stages of the disease.
Immunohistochemistry of melanomas for BRM, p16INK4a and  BRG1 Figure 7
Immunohistochemistry of melanomas for BRM, 
p16INK4a and BRG1. Melanoma samples were stained for 
p16INK4a and BRG1 with immunohistochemistry using DAB. 
BRM was stained using red fluorescence. Positive staining 
examples are presented in the right panel with no primary 
antibody control from the corresponding region in the left 
panel.
Table 2: BRG1 is frequently lost in melanomas
BRM p16INK4a BRG1
Primary 83% (19/23) 21% (5/24) 28% (5/18)
Metastatic 78% (21/27) 19% (4/21) 35% (7/20)
Total 80% (40/50) 20% (9/45) 32% (12/38)
Immunohistological detection of BRG1, p16INK4a and BRM in primary 
and metastatic melanomas showing the proportion of samples with 
detectable positive staining.Molecular Cancer 2009, 8:4 http://www.molecular-cancer.com/content/8/1/4
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The identification of BRG1 as a potential tumor suppres-
sor in melanoma adds to the increasing evidence implicat-
ing the SWI/SNF chromatin remodelling complex in
tumor development. BRG1 mutations have been identi-
fied in small cell lung carcinomas [34] and loss of BRG1
expression or mislocalisation of BRG1 to the cytoplasm
has been associated with poor prognosis in this malig-
nancy [14,15]. Another study showed that 71% of neu-
roendocrine carcinomas of the cervix had lost BRG1
expression [13] and BRG1 has been implicated in breast
cancer through its role in estrogen receptor dependent
transcription [35], its interaction with the breast cancer
susceptibility gene BRCA1 [27] and because BRG1 hap-
loinsufficient mice are prone to mammary tumors [23].
Furthermore, BRG1 is often lost or mutated in various
tumor cell lines including cells derived from pancreatic,
ovarian, lung, brain and colon cancer [12]. In primary
melanoma, the chromosomal region of BRG1 (19p13.2)
is not deleted at high frequency [36], nevertheless, trans-
locations in this chromosomal region have been associ-
ated with the disease in three cases [37].
Conclusion
We have identified BRG1 as a novel binding partner of the
tumor suppressor p16INK4a and confirmed this interaction
in normal cells. Together with our immunohistologic data
confirming frequent BRG1 loss in primary melanomas,




The Matchmaker2 Gal4 yeast two-hybrid system (Clon-
tech, Mountain View, CA, USA) was used to screen for
p16INK4a binding partners in the Y190 yeast strain with
p16INK4a cloned into the pAS2 vector in frame to the Gal4
binding domain and a human brain cDNA library cloned
into the pACT2 vector in frame with the Gal4 transactiva-
tion domain (Clontech, Mountain View, CA, USA)
according to the manufacturers instructions.
Cell culture
U2OS, SAOS-2 (osteosarcoma), HCT116 (colon cancer),
NCI-H1299 (lung cancer, are referred to as H1299
throughout this manuscript), C33A (cervical cancer), SW-
13 (adrenocarcinoma), WS-1 (normal human fibroblasts)
and WMM1175_wtp16 (melanoma) cells were grown in
DMEM media with 10% foetal bovine serum and in case
of WMM1175_wtp16 cells this was supplemented with
250 μg/ml Hygromycin and 500 μg/ml geneticin (Invitro-
gen, Carlsbad, CA, USA). Transfections were performed
with FuGene (Roche, Mannheim, Germany).
Stable BRG1 silenced p16INK4a inducible WMM1175 clones
5 × 105 WMM1175_wtp16 cells were transfected with 4 μg
of a BRG1 targeting siRNA (5'gatccGCATGCACCAGATGC
ACAAgttcaagagaCTTGTGCATCTGGTGCATGttttttggaaa3')
cloned into the pSilencerPuro vector (Ambion, Austin,
Texas, USA) or a control siRNA, targeting the luciferase
gene, in the same vector supplied by Ambion. After selec-
tion with puromycin (2 μg/ml media) clones appeared
after 20 days and were expanded, maintained with DMEM
media including hygromycin, geneticin and puromycin
and tested for BRG1 silencing and p16INK4a inducibility.
Antibodies
Mouse anti-β-actin (AC-74, Sigma, Castle Hill, NSW, Aus-
tralia), mouse anti-Flag (M2, Sigma, Castle Hill, NSW,
Australia), rabbit anti p16INK4a antibody (Western and
immunohistochemistry, N-20, SantaCruz, Santa Cruz,
CA, USA), mouse anti-p16INK4a antibody (immunoprecip-
itation, 2B4D11, Zymed Laboratories, San Francisco, CA,
USA), mouse anti-BRG1 antibody (Western, G7, San-
taCruz, Santa Cruz, CA, USA), rabbit anti-BRG1 antibody
(immunohistochemistry, H-88, Santa Cruz, Santa Cruz,
CA, USA), rabbit anti-MYC (A14, SantaCruz, Santa Cruz,
CA, USA), Ki67 (MIB-1, Dako, Glostrup, Denmark), goat
anti-BRM (Western, N-19, Santa Cruz, Santa Cruz, CA,
USA), rabbit anti-BRM (immunohistochemistry, [38]),
mouse anti-CDK4 (C8218, Sigma, Castle Hill, NSW, Aus-
tralia), mouse anti-CDK6 (MS-451-P0, Neomarker,
Union City, CA, USA), rabbit anti-phosphorylated pRb
(Ser807/811, Cell Signalling, Boston, MA, USA), mouse
anti-pRb (G3-245, BD Pharmingen, Franklin Lakes, NJ,
USA), mouse anti-topoisomerase II (Ab1, Oncogene, San
Diego, CA, USA),
Immunoprecipitation
24 hours post seeding U2OS cells (2 × 106), they were
transfected with 7 μg pCMV-Myc5b-p16 and either 10.5
μg pcDNA3-BRG1-Flag [39] or 10.5 μg pCMV-Flag5b vec-
tor (Promega, Madison, Wisconsin, USA). Cells were har-
vested 24 hours post transfection, lysed in IP-buffer (50
mM Tris pH7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40,
0.25% sodium deoxycholate, protease inhibitors (Com-
plete tablets, Roche, Mannheim, Germany)) and immu-
noprecipitation was performed with mouse-anti-Flag
antibody or a matched mouse IgG coupled to tosyl-acti-
vated Dynal beads (Dynal Biotech, Oslo, Norway) follow-
ing the manufacturers instructions. Proteins were
separated on a 5–15% gradient SDS-PAGE gel, transferred
to PVDF membranes (Millipore, Billerica, MA, USA) and
probed for FLAG-BRG1 and MYC-p16INK4a  with the
mouse-anti-FLAG antibody or a rabbit anti-p16INK4a anti-
body.
For immunoprecipitations of endogenous BRG1
WMM1175_wtp16 cells were induced to express p16INK4aMolecular Cancer 2009, 8:4 http://www.molecular-cancer.com/content/8/1/4
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with 4 mM IPTG or mock treated for 72 hours; alterna-
tively passage 20 WS-1 human dermal fibroblasts were
used. Nuclear pellets were produced using low salt buffer
(10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1
mM EGTA, 1 mM DTT) and lyzed in IP-buffer with pro-
tease inhibitors. 5 mg of nuclear lysate was used for
immunoprecipitation using a mouse anti-p16INK4a anti-
body or a matched mouse IgG. Protein antibody com-
plexes were purified using protein-A-agarose (Santa Cruz,
Santa Cruz, CA, USA). Immunoblotting was performed as
described above, endogenous BRG1 was detected with a
mouse anti-BRG1 antibody.
Immunocytostaining
SW-13 cells were seeded at 105 cells on cover slips into 6-
well plates and transfected 24 hours post seeding with 1
μg pCMV-MYC5b-p16 and 1.5 μg pcDNA3-BRG1-FLAG.
Cells were fixed with methanol:acetone (1:1) for one
minute, washed with PBS and probed with mouse anti-
FLAG and rabbit anti-MYC antibodies and secondary
Alexa Fluor 594 nm goat-anti-mouse and Alexa Fluor 488
nm goat anti-anti-rabbit antibodies (Invitrogen, Carlsbad,
CA, USA). Images were taken with a BX-51 microscope
and a SPOT camera and a FV1000 confocal microscope
(Olympus, Center Valley, PA, USA).
WMM1175_p16INK4a cells silenced for BRG1 or expressing
a control silencing molecule were seeded after 1, 3, 5 days
induction with 4 mM IPTG at 4 × 104 cells on cover slips
and fixed 8 hours later with 2% formaldehyde, 0.2% glu-
taraldehyde, 7 mM Na2HPO4, 1.5 mM KH2PO4, 140 mM
NaCl, and 2.6 mM KCl and stained for SA-β-galactosidase,
DAPI, Ki67, p16INK4a and BRG1. Images were taken with a
BX-51 microscope and a SPOT camera (Olympus, Center
Valley, PA, USA).
Western blotting
50 μg total cell lysate or nuclear lysate was separated on
15% SDS-PAGE gels or 5–15% gradient SDS-page gels,
transferred to PVDF membranes (Millipore, Billerica, MA,
USA) and probed for β-actin p16INK4a, BRG1, BRM, pRb,
CDK6, phoshorylated pRb and p16INK4a.
Cell proliferation assay
WMM1175_p16INK4a cells silenced for BRG1 or expressing
a control silencing molecule were seeded at 103 cells per
well in 96 well plates. For each day one plate was assayed
for MTS levels using a CellTitre 96 Aqueous One Solution
Proliferation assay (Promega, Madison, Wisconsin, USA)
according to the manufacturer's protocol using a Victor2
1420 Multilable counter (Perkin Elmer).
Cell cycle distribution
105 cells were seeded per well into 6-well plates and 24
hours later transfected with 1 μg pCMV-MYC5b-p16 and/
or 1.5 μg pcDNA3-BRG1-FLAG or 2.5 μg pCMV-MYC5b
vector plus 250 ng pEGFPspectrin. Total transfected DNA
was adjusted to 2.75 μg with pCMV-MYC5b vector. Cells
were harvested 48 hours post transfection and fixed in
4°C 70% ethanol for at least 1 hour and stained with 50
μg/ml propidium iodide and 50 μg/ml RNasesA in PBS
and analyzed using a FACScalibur and ModFit software
(Becton Dickinson, Franklin Lakes, NJ, USA). Percent S-
phase change was calculated (percent S-phase vector con-
trol – percent S-phase sample) × 100/percent S-phase vec-
tor control.
WMM1175_wtp16 cells expressing a siRNA targeting
BRG1 or a control siRNA molecule targeting luciferase
were induced for 1, 3 or 5 days with 4 mM IPTG or mock
treated. For each time point the cell cycle distribution was
determined as described above.
Immunohistochemistry
Paraffin-embedded formaldehyde fixed primary (Breslow
depth of invasion > 2 mm) or metastatic melanomas were
cut at 4 mm onto Superfrost Plus slides and dried at 60°C
for 1 hour. Sections were rehydrated through histolene
and ethanol, heated in antigen retrieval buffer (Dako,
Glostrup, Denmark) overnight at 70°C. Slides were
placed in 3% hydrogen peroxide for 10 min then blocked
for 1 hour with 50% normal goat serum (Serum Australis,
Tamworth, NSW, Australia) diluted in 1% Tween 20/tris
buffered saline (TTBS). Samples were incubated with pri-
mary antibodies for 1 hour at dilutions indicated. For
p16INK4a and BRG1 slides were incubated for 30 minutes
with biotinylated goat anti-rabbit (Dako, Glostrup, Den-
mark) diluted 1:400 in TBT (1%BSA in TTBS) and finally
for 30 minutes with biotinylated-HRP/streptavidin (Invit-
rogen, Carlsbad, CA, USA) diluted in TBT. Antibodies
were detected using 3,3'-diaminobenzidine tetrachloride
(DAB; Invitrogen, Carlsbad, CA, USA), counter stained
with Mayers Haemotoxylin (Sigma, Castle Hill, NSW,
Australia), dehydrated and mounted using Normount
(Fronine, Riverstone, NSW, Australia). For BRM, slides
were incubated for 1 hour with Alexa Fluor goat anti-rab-
bit 594 nm (Invitrogen, Carlsbad, CA, USA) diluted
1:1000 with DAPI (Sigma, Castle Hill, NSW, Australia)
diluted 1:2000 in TBT. Slides were washed then mounted
using 3% n-propylgallate/50% glycerol. Primary antibod-
ies used were mouse anti-p16 (1:200), rabbit anti-BRG1
(1:100) and rabbit anti-BRM1 (1:400). Sections were
scored for staining intensity as 0 (equal to control), 1
(very weak positive)), 2 (positive) and 3 (strong positive)
and the proportion of tumor tissue with positive staining
as 0 (none), 1 (< 10%), 2 (< 50%) and 3 (> 50%). Tumors
were considered to have detectable positive staining when
the (intensity score) × (proportion staining score) was > 1.
Only tumor samples with enough tissue for staining of at
least two of the proteins were included in the study.Molecular Cancer 2009, 8:4 http://www.molecular-cancer.com/content/8/1/4
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Appropriate negative and positive controls were used with
each batch of immunostaining. This study is covered by
the Sydney South West Area Health Service Ethics Review
Committee (RPAH Zone) Protocol No. X08-0155 &
HREC Ref. 08/RPAH/262 – "Histological and Immuno-
histological Analysis of Melanocytic Tumours".
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